Forte Biosciences (FBRX) Amortizatization of Intangibles (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Amortizatization of Intangibles of $7000.0 for Q1 2026, down 97.08% year-over-year from $240000.0 in Q1 2025, and up 177.78% quarter-over-quarter from -$9000.0 in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Amortizatization of Intangibles (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Amortizatization of Intangibles for 8 consecutive years, with $7000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 97.08% year-over-year to $7000.0; the TTM figure through Mar 2026 stood at $4000.0 (down 98.98% YoY), while the FY2025 annual figure was $237000.0, up 50.0% from the prior year.
- Amortizatization of Intangibles climbed to $7000.0 in Q1 2026 per FBRX's latest filing, from -$9000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $240000.0 in Q1 2025 and bottomed at -$9000.0 in Q3 2024.
- Historically, Amortizatization of Intangibles has averaged $50250.0 across 3 years, with a median of $6000.0 in 2024.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 3900.0% in 2025 and fell as far as 105.77% in 2025.
- Forte Biosciences' Amortizatization of Intangibles stood at $156000.0 in 2024, then sank by 105.77% to -$9000.0 in 2025, then jumped by 177.78% to $7000.0 in 2026.
- Business Quant data shows FBRX's Amortizatization of Intangibles at $7000.0 in Q1 2026, -$9000.0 in Q4 2025, and $6000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | 1.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Mn |
| Mar 31, 2026 | 7,000.00 |
| Dec 31, 2025 | -9,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2020 | -103,000.00 |
| Mar 31, 2019 | 41,000.00 |
| Mar 31, 2018 | 46,000.00 |
| Dec 31, 2017 | -422,000.00 |
| Sep 30, 2017 | 148,000.00 |
| Jun 30, 2017 | 146,000.00 |
| Mar 31, 2017 | 147,000.00 |
| Dec 31, 2016 | -414,000.00 |
| Sep 30, 2016 | 143,000.00 |
| Jun 30, 2016 | 140,000.00 |
| Mar 31, 2016 | 140,000.00 |